Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the potential of topical ruxolitinib as a treatment for alopecia universalis and acknowledges the need for alternatives to systemic JAK inhibitors due to the risk of serious side effects.

This study reports that adjusting the valence states of Mo in Pluronic F127-coated MoO3-x nanozymes enhances their selective H2O2-related catalytic activity, showing promise in acute kidney injury treatment and enabling real-time monitoring of therapy effectiveness through ROS-responsive photoacoustic imaging.

This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.

Tocilizumab might be an effective treatment for COVID-19.

This report describes a case of a 19-year-old woman experiencing severe recurrent angioedema with airway issues, leading to multiple emergency visits and unsuccessful treatment with typical steroid-sparing agents.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

In this study using C3H/HeJ mice, a single subcutaneous injection of the fusion protein PTH-CBD increased anagen hair follicle counts and promoted hair regrowth comparably to daily oral ruxolitinib, potentially by enhancing beta-catenin production and stimulating anagen transition.

This study suggests that combining testosterone and letrozole may accelerate puberty in boys with constitutional delay by increasing serum androgen bioactivity and facilitating pubertal progression.

This meta-analysis reports that trastuzumab deruxtecan is effective and has an acceptable safety profile for treating HER2-low or positive advanced breast cancer, although further research is recommended to support individualized treatment strategies.

This study reports on a zinc-coordinated tri-enzyme nanogel system (Zn@nGSC) that mimics natural enzymatic processes to enhance enzymatic activity and cascade efficiency, showing potential in wound healing, hyperglycemia treatment, and antibacterial effects in a murine model of post-pancreatectomy.

In this randomized, placebo-controlled study, Titagen® was found to improve skin, hair, and nail health in adults consuming 5g daily, and reduce pain and improve quality of life for osteoarthritis patients taking 10g daily, without related adverse events.

In this study, researchers developed an optimized production process for the herbal tincture "Stimufit," intended for topical use in treating telogen alopecia, using 40% ethanol and a specific extraction method.

In this study, researchers created a core-shell nanozyme, CeO2@ZIF-8/Au, which autonomously regulates ROS levels to efficiently eliminate bacteria, reduce inflammation, and promote wound healing by balancing ROS generation and scavenging in response to environmental conditions.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.

This study suggests that combining GliSODin(®) Skin Nutrients with tazarotene cream significantly benefits facial fine wrinkles, photodamage, moisture, and elasticity compared to tazarotene alone.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This review discusses the role of tyrosine kinase signaling pathways in autoimmune and inflammatory skin diseases and reports no new clinical results, highlighting ongoing research into small-molecule tyrosine kinase inhibitors as potential treatments.

In this study, incorporating cetirizine into transferosome formulations significantly enhanced hair growth in mice and boosted IGF-1 and VEGF levels, suggesting that this method could be a promising alternative to traditional hair growth treatments, though further studies are needed to confirm its safety and suitability.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

Terazosin and finasteride together cause no major issues.

In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

This study found that the serine protease inhibitor ONO-3403 significantly suppressed tumor growth in mice with induced squamous cell carcinoma without apparent side effects, suggesting its potential for cancer treatment.

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

In this study, Tolterodine Tartrate significantly improved symptoms of overactive bladder and showed fewer adverse reactions compared to the control group treatment.